Biogen vs GE HealthCare Technologies

Biogen (BIIB), health care, and GE HealthCare Technologies (GEHC), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Biogen and GE HealthCare Technologies are valued at about the same: $37.1B and $37B. Biogen trades at 109 times earnings and GE HealthCare Technologies at 17.3. Over the past year Biogen's share price has moved +49.1% and GE HealthCare Technologies's +16.8%.

Key facts

Biogen market value
$37.1B
GE HealthCare Technologies market value
$37B
Biogen P/E
109
GE HealthCare Technologies P/E
17.3
Biogen revenue
$9.9BFY to 2025-12-31
GE HealthCare Technologies revenue
$20.6BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Biogen vs GE HealthCare Technologies: every measure side by side
Measure Biogen GE HealthCare Technologies
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$37.1Bhigher$37Blower
Revenue$9.9Blower$20.6Bhigher
Earnings$1.3Blower$2.1Bhigher
Employees7,500lower54,000higher
Total assets$29.4Blower$36.9Bhigher
Valuation
P/E109higher17.3lower
P/S3.7higher1.8lower
P/B2.0lower3.2higher
Dividend yield0.00%lower0.17%higher
Profitability
Operating margin—13.4%
Balance sheet
Net assets$18.3Bhigher$10.4Blower
Total liabilities$11.2Blower$26.3Bhigher
Total debt$6.3Blower$10.5Bhigher
Cash on hand$3Blower$4.5Bhigher
Price change
Today-0.34%higher-1.35%lower
1 year+49.1%higher+16.8%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Percentages are each holding's share of that investor's reported portfolio. Who owns BIIB · Who owns GEHC

Further comparisons

Learn

Questions and answers

Which is bigger, Biogen or GE HealthCare Technologies?

By market value, Biogen is the larger: $37.1B against $37B for GE HealthCare Technologies. By revenue in its latest fiscal year, GE HealthCare Technologies is the larger: $20.6B against $9.9B for Biogen.

Which has the higher P/E ratio?

Biogen: 109, against 17.3 for GE HealthCare Technologies. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

Which has the higher dividend yield?

GE HealthCare Technologies: 0.17%, against 0.00% for Biogen. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

GE HealthCare Technologies: $10.5B, against $6.3B for Biogen. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Biogen and GE HealthCare Technologies?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold Biogen and 11 hold GE HealthCare Technologies.

Cite this page

Funkfolio, “Biogen vs GE HealthCare Technologies”, data as of 18 November 2026. https://funkfolio.com/compare/biib-vs-gehc

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.